Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XNCR

Xencor Inc

Dec 30 • 04:00PM ET

15.03

-0.14 -0.92 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB ALNY INCY BLUE SGMO FGEN PGEN ADAP

| Held by: IJR VTI IWM XBI VB VXF IJS SPSM IWN VBK

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.78	Insider Own	6.08%	Shs Outstand	71.34M	Perf Week	-5.89%
Market Cap	1.07B	Forward P/E	-	EPS next Y	-2.79	Insider Trans	-4.14%	Shs Float	67.07M	Perf Month	-13.22%
Enterprise Value	804.67M	PEG	-	EPS next Q	-0.60	Inst Own	114.16%	Short Float	14.17%	Perf Quarter	28.13%
Income	-130.82M	P/S	7.15	EPS this Y	48.72%	Inst Trans	-3.60%	Short Ratio	9.14	Perf Half Y	86.25%
Sales	150.13M	P/B	1.71	EPS next Y	-52.06%	ROA	-14.00%	Short Interest	9.50M	Perf YTD	-34.60%
Book/sh	8.76	P/C	2.28	EPS next 5Y	9.95%	ROE	-19.61%	52W High	24.66 -39.05%	Perf Year	-39.40%
Cash/sh	6.60	P/FCF	-	EPS past 3/5Y	- -	ROIC	-16.81%	52W Low	6.92 117.20%	Perf 3Y	-41.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.22% -6.75%	Gross Margin	92.71%	Volatility	3.37% 5.17%	Perf 5Y	-67.32%
Dividend TTM	-	EV/Sales	5.36	EPS Y/Y TTM	48.43%	Oper. Margin	-91.29%	ATR (14)	0.79	Perf 10Y	4.45%
Dividend Ex-Date	-	Quick Ratio	5.99	Sales Y/Y TTM	38.16%	Profit Margin	-87.14%	RSI (14)	41.93	Recom	1.21
Dividend Gr. 3/5Y	- -	Current Ratio	5.99	EPS Q/Q	88.80%	SMA20	-7.98%	Beta	0.96	Target Price	28.00
Payout	-	Debt/Eq	0.32	Sales Q/Q	18.00%	SMA50	-2.78%	Rel Volume	0.37	Prev Close	15.17
Employees	250	LT Debt/Eq	0.24	Earnings	Nov 05 AMC	SMA200	37.42%	Avg Volume	1.04M	Price	15.03
IPO	Dec 03, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	88.38% -26.86%	Trades		Volume	380,258	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Oct-29-25	Upgrade	Barclays	Underweight → Overweight	$23
Sep-17-25	Resumed	Barclays	Underweight	$6
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$12
Apr-21-25	Initiated	William Blair	Outperform
Dec-12-24	Initiated	Wells Fargo	Overweight	$37
Dec-02-24	Upgrade	Piper Sandler	Neutral → Overweight	$20 → $30
Apr-16-24	Reiterated	BTIG Research	Buy	$56 → $38
Feb-28-24	Downgrade	Piper Sandler	Overweight → Neutral	$37 → $24
May-19-23	Initiated	BofA Securities	Buy	$42
Dec-06-22	Initiated	Cowen	Outperform
Oct-13-22	Upgrade	Raymond James	Outperform → Strong Buy	$58
Sep-21-22	Initiated	JP Morgan	Overweight	$37
Jul-06-22	Resumed	Canaccord Genuity	Buy	$50
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$54
Jan-21-22	Initiated	SMBC Nikko	Outperform	$60
Dec-15-21	Initiated	H.C. Wainwright	Buy	$61
Oct-15-21	Resumed	BTIG Research	Buy	$56
Feb-24-21	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Mar-04-20	Initiated	Barclays	Underweight	$28

Show Previous Ratings

Dec-09-25 07:00AM	Xencor Announces Extension of U.S. Patent Term on Certain Xtend Antibodies (Business Wire)
Nov-10-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire) +8.22%
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2025 Financial Results (Business Wire)
06:08AM	Loading…
06:08AM	Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner (TipRanks)
Nov-04-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-24-25 12:30PM	Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma (Business Wire) +7.05%
Oct-21-25 08:01AM	Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily) +6.03%
Oct-14-25 12:45PM	Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire) -10.96%
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
Sep-18-25 10:05AM	Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks) +8.43%
Sep-08-25 12:30AM	RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating (Insider Monkey)
04:01PM	Loading…
Aug-27-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Aug-08-25 09:05AM	Xencor price target lowered to $26 from $31 at Wedbush (TipRanks)
Aug-06-25 05:35PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.79%
04:36PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 04:01PM	Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors (Business Wire)
07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
May-07-25 05:30PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.61% +10.08%
04:26PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports First Quarter 2025 Financial Results (Business Wire)
May-01-25 10:01AM	Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-29-25 04:01PM	Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease (Business Wire)
Apr-11-25 10:15AM	Xencor, Inc.: No Major Near Term Catalysts (Seeking Alpha) +7.83%
Apr-10-25 12:00PM	Xencor (XNCR) Upgraded to Buy: Here's Why (Zacks) -10.10%
Mar-13-25 04:01PM	Xencor Appoints Todd Simpson to Board of Directors (Business Wire)
09:15AM	Loading…
Feb-27-25 09:15AM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
08:01AM	Xencor Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 09:35AM	Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-21-25 09:35AM	Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround (Zacks) +6.29%
Jan-20-25 09:35AM	After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) (Zacks)
Jan-15-25 09:35AM	Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks (Zacks)
Jan-14-25 12:00PM	Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -5.68%
Dec-12-24 12:00PM	All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy (Zacks)
Dec-04-24 09:55AM	Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet (Zacks)
Nov-26-24 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Nov-18-24 09:55AM	Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade (Zacks)
Nov-14-24 09:55AM	Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-06-24 05:15PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.39%
04:11PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 07:00AM	Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease (Business Wire)
Nov-01-24 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? (Zacks)
Oct-29-24 10:01AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Xencor Inc Holdings (GuruFocus.com)
Oct-16-24 09:55AM	Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know (Zacks)
Oct-10-24 08:09AM	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Business Wire)
Oct-04-24 08:01AM	Xencor Announces Upcoming Change to Board of Directors (Business Wire)
Sep-12-24 04:01PM	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
04:55AM	Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? (Zacks)
Sep-11-24 06:31AM	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Business Wire) +10.45%
Sep-10-24 04:01PM	Xencor Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-09-24 07:31AM	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Business Wire) +22.93%
Sep-06-24 08:01AM	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Business Wire)
Aug-05-24 09:55PM	XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) -7.30%
05:15PM	Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2024 Financial Results (Business Wire)
Jun-13-24 08:01AM	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Business Wire)
May-10-24 01:45PM	Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
06:20AM	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating (MT Newswires)
May-09-24 11:54PM	XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	Xencor Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 10:00AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-03-24 07:01PM	Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares (GuruFocus.com)
May-02-24 03:31AM	Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? (Zacks)
Apr-09-24 08:01AM	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Business Wire)
Mar-08-24 05:01PM	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Mar-07-24 05:00PM	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Feb-28-24 04:01PM	Xencor to Present at Upcoming Investor Conferences (Business Wire) -14.06%
09:35AM	Q4 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
08:38AM	Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:20PM	Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:26PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:31PM	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update (Business Wire)
Feb-19-24 03:37AM	Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains? (Zacks)
Feb-15-24 10:00AM	Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks) +5.97%
Jan-03-24 04:01PM	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:55AM	Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Jan-02-24 08:01AM	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy (Business Wire) +6.03%
Dec-30-23 05:02PM	Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares (GuruFocus.com)
Nov-21-23 04:01PM	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire) -6.99%
Nov-09-23 02:19PM	Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:21AM	Xencor pulls back from Genentech cancer pact to cut costs, as CytomX drops ex-AbbVie ADC (FierceBiotech.com) -7.01%
Nov-07-23 04:39PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Sells Portion of Royalties and Milestones from Ultomiris and Monjuvi to OMERS Life Sciences for $215 Million (Business Wire)
04:01PM	Xencor Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-03-23 12:01PM	Xencor Presents Preclinical Data from Multiple XmAb Research Programs at the SITC Annual Meeting (Business Wire) +5.49%
Oct-31-23 04:01PM	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 (Business Wire)
12:00PM	Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-26-23 08:01AM	Xencor Announces Planned Retirement of Chief Financial Officer John Kuch (Business Wire)
Oct-17-23 04:21AM	Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Option Exercise	12.51	73,367	917,821	309,941	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 22 '25	Option Exercise	12.51	6,311	78,951	242,885	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Sale	15.72	73,367	1,153,329	236,574	Dec 23 04:02 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Option Exercise	12.51	114,377	1,430,856	581,012	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 22 '25	Option Exercise	12.51	10,624	132,906	477,259	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Sale	15.71	114,377	1,796,863	466,635	Dec 23 04:01 PM
Desjarlais John R	Officer	Dec 19 '25	Proposed Sale	15.72	73,367	1,153,517		Dec 19 04:19 PM
Dahiyat Bassil I	Officer	Dec 19 '25	Proposed Sale	15.71	114,377	1,796,943		Dec 19 04:13 PM
Montgomery Alan Bruce	Director	Jun 16 '25	Sale	9.22	2,215	20,422	20,611	Jun 16 07:35 PM
GUSTAFSON KURT A	Director	Jun 16 '25	Sale	9.22	2,993	27,595	20,183	Jun 16 07:31 PM
GORMAN KEVIN CHARLES	Director	Jun 16 '25	Sale	9.22	3,173	29,255	18,905	Jun 16 07:30 PM
Feigal Ellen	Director	Jun 16 '25	Sale	9.22	2,993	27,595	19,183	Jun 16 07:26 PM
RANIERI RICHARD J	Director	Jun 16 '25	Sale	9.22	2,993	27,595	19,183	Jun 16 07:22 PM
GUSTAFSON KURT A	Director	Jun 16 '25	Proposed Sale	9.19	2,993	27,506		Jun 16 12:53 PM
Montgomery Alan Bruce	Director	Jun 16 '25	Proposed Sale	9.22	2,215	20,422		Jun 16 12:30 PM
GORMAN KEVIN CHARLES	Director	Jun 16 '25	Proposed Sale	9.22	3,173	29,255		Jun 16 12:14 PM
Feigal Ellen	Director	Jun 16 '25	Proposed Sale	9.22	2,993	27,595		Jun 16 12:07 PM
RANIERI RICHARD J	Director	Jun 16 '25	Proposed Sale	9.22	2,993	27,595		Jun 16 10:29 AM
Valente Nancy	EVP, Chief Development Officer	May 02 '25	Sale	11.03	4,616	50,914	49,169	May 06 04:40 PM
Valente Nancy	Officer	May 02 '25	Proposed Sale	11.03	4,616	50,914		May 02 03:23 PM
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Apr 10 '25	Sale	8.06	3,750	30,233	61,348	Apr 14 04:13 PM
Cornelissen Bart Jan	Officer	Apr 10 '25	Proposed Sale	8.06	3,750	30,233		Apr 10 03:21 PM
Valente Nancy	EVP, Chief Development Officer	Mar 10 '25	Sale	13.60	2,565	34,877	53,785	Mar 11 04:28 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 10 '25	Sale	13.60	5,740	78,047	63,507	Mar 11 04:26 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 10 '25	Sale	13.60	9,697	131,851	236,574	Mar 11 04:25 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 10 '25	Sale	13.60	19,716	268,080	465,419	Mar 11 04:23 PM
Eckert Celia	Officer	Mar 10 '25	Proposed Sale	13.60	5,740	78,047		Mar 10 04:26 PM
Valente Nancy	Officer	Mar 10 '25	Proposed Sale	13.60	2,565	34,877		Mar 10 04:21 PM
Desjarlais John R	Officer	Mar 10 '25	Proposed Sale	13.60	9,697	131,851		Mar 10 04:19 PM
Dahiyat Bassil I	Officer	Mar 10 '25	Proposed Sale	13.60	19,716	268,080		Mar 10 04:17 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 03 '25	Option Exercise	15.69	3,542	55,574	216,420	Feb 03 04:54 PM
Dahiyat Bassil I	PRESIDENT & CEO	Feb 03 '25	Option Exercise	15.69	8,808	138,198	375,390	Feb 03 04:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XNCR

Xencor Inc

Upgrade your FINVIZ experience